A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.

Gavin Giovannoni,Alexey Boyko,Jorge Correale,Gilles Edan,Mark S Freedman,Xavier Montalban,Kottil Rammohan,Dusan Stefoski,Bassem Yamout,Thomas Leist,Aida Aydemir,Laszlo Borsi,Elisabetta Verdun di Cantogno

Neurodegenerative disease management（2023）

引用 0|浏览7

暂无评分

摘要

The results obtained from CLASSIC-MS show that the benefits of taking cladribine tablets carry on even when patients stop taking the treatment. : NCT03961204 (CLASSIC-MS) (ClinicalTrials.gov).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要